Noninvasive prediction of fibrosis in patients with chronic hepatitis C
✍ Scribed by Dominique Thabut; Marion Simon; Robert P. Myers; Djamila Messous; Vincent Thibault; Françoise Imbert-Bismut; Thierry Poynard
- Book ID
- 111722163
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 64 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Hepatic fibrosis is the main determinant of clinical outcomes of chronic hepatitis C. Liver histology is frequently considered the gold standard for assessing hepatic fibrosis. However, liver biopsy is associated with sampling error, interobserver variability, and potential complications. Thus, ther
A model was constructed consisting of clinical and serum variables to discriminate between hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with and without significant fibrosis (stages 2-4 vs. stages 0-1). Consecutive treatment-naive CHB patients who underwent liver biopsy
Liver fibrosis is the main predictor of the progression of chronic hepatitis C, and its assessment by liver biopsy (LB) can help determine therapy. However, biopsy is an invasive procedure with several limitations. A new, noninvasive medical device based on transient elastography has been designed t